Table 2.

Subsequent anticancer treatments.^a

Subsequent treatment, n (%)	Placebo + vemurafenib (n = 227)	Cobimetinib + vemurafenib (n = 240)
≥1 subsequent treatment	130 (57)	122 (51)
Chemotherapy	36 (16)	33 (14)
Targeted therapy	40 (18)	38 (16)
BRAF inhibitor	25 (11)	21 (9)
Combined BRAF and MEK inhibitor	16 (7)	19 (8)
MEK inhibitor	1 (<1)	3 (1)
Immunotherapy	94 (41)	82 (34)
Ipilimumab	83 (37)	53 (22)
Anti–PD-1 agents	42 (19)	44 (18)
Ipilimumab plus anti–PD-1	4 (2)	6 (3)
Other	1 (<1)	0

^aIn patients who discontinued study treatment for reasons other than death.